Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2019: ANNOUNCEMENT: Lille Juily 2-4, 2019: BMSystems invited as speaker at ANTIMIC 2019: Bacteriophages, Genius and success of precision medicine in infections (ATC HCl) and new tracks for microbiote “surgery” controt with GEMMA microbiota &Autism H2O2O program
      
  • 2019: PRESS-RELEASE: Paris May 30, 2019 : Manuel GEA, CEO BMSystems, rejoint l’Advisory Board Pharma/Santé de Bolero pour renforcer leurs offres et accélérer la convergence recherche clinique et données de vraie vie

  • 2019: ANNOUNCEMENT: Paris May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019). Meet us to discover our Alzheimer's and Parkinson’s diseases solutions.
      
  • 2019: ANNOUNCEMENT: BMSystems will be participating to  Polepharma microbiota conference (the N°1 pharmaceutical cluster in Europe) event to present its GEMMA microbiota &Autism H2O2O program !
      
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: www.gemma-project.eu for the World Autism Awareness Day.
     
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

Bio-Modeling Systems is the world’s first Mechanisms-Based Medicine company that successfully changed the discovery paradigm, addressing the complexity of life sciences mechanisms and the digital « garbage in garbage out » reality through CADI*Discovery.

We offer to R&D & Translational Medicine Executives, robust alternative decision-making to de-risk, save time, costs, and novel cost-effective diagnostics/therapies for their businesses.

Created in 2004, profitable since 2006, thanks to our recurrent clients, we already confirmed in Pharma, Biotech, Cosmetics, Nutrition and digital-Health, CADI™ Discovery capability to achieve:

  1. A world's first in neurodegenerative diseases (publication) with CEA: 2 awards (US & Europe).

  2. Pherecydes-Pharma: First BMSystems' therapeutic spin-off,against MR infections therapies,  3 patents, publication, world's first clinical trial with bacteriophages in Phase I/II, Compassionate Use Success.

  3. CEA/BMSystems collaborative research in CNS that led to the co-owned patent with a worldwide exclusive license to Theranexus, CEA’s spin-off currently in Phase II,

  4. Successful development of Mechanisms-Based Cosmetic to address industry major challenges,

  5. 14 CADI™ successes independently validated by our clients/partners.

Latest news: BMSystems is the Integrative Biology partner of GEMMA (Genome, Environment, Microbiome and Metabolome in Autism) project with €14.2M H2020 funding  

We warmly invite you to download our management summary,  our Short corporate Presentation

*Computer Augmented Deductive Intelligence platform.

 

The life-modeling issue: Are we using the right concepts in the righ order?

 

CADI™ : Computer Augmented Deductive Intelligence)